Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.39 |
| ▸ | EGFR | P00533 | 8/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | BLK | P51451 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447940 | 0.84 | RIPK2 (0.40) | RIPK2 | |
| SCHEMBL17448005 | 0.79 | RAB9A (0.46) | RIPK2 | |
| SCHEMBL17447921 | 0.77 | BTK (0.38) | BTKEGFR | |
| SCHEMBL17447941 | 0.77 | BTK (0.38) | BTKEGFR | |
| SCHEMBL17447944 | 0.77 | BTK (0.38) | BTKEGFR | |
| SCHEMBL17447797 | 0.75 | BTK (0.33) | BTKEGFR | |
| SCHEMBL17447960 | 0.75 | BTK (0.38) | BTKEGFR | |
| SCHEMBL17447963 | 0.74 | BTK (0.39) | BTKEGFR | |
| SCHEMBL17447998 | 0.74 | BTK (0.40) | BTKEGFR | |
| SCHEMBL17447839 | 0.74 | BTK (0.35) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106687446-B | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible kinase inhibitors of T790M/WT-EGFR and uses thereof | 百济神州(北京)生物科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| WO-2016008411-A1 | 5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF | BEIGENE, LTD. (KY) | 2016-01-21 | — | — | WO | disclosed |